Eric D. Shaff sold $3,754 of MCRB
CEO and President at Seres Therapeutics, Inc.. 217 shares at an average of $17.30, traded Nov 15, 2025, filed Nov 18, 2025.
Score components
- +15RoleDirector
- 0Trade size$4k at market
- 0Share of holdings soldSold 1.9% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-286235, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 15, 2025 | MOption exercise Common Stock10b5-1 | +390 | - | - | 10,999 | Nov 18, 2025 |
| Nov 15, 2025 | MOption exercise Common Stock10b5-1 | +331 | - | - | 11,330 | Nov 18, 2025 |
| Nov 15, 2025 | SOpen-market sale Common Stock10b5-1 | -217 | $17.30 | $3,754 | 11,113 | Nov 18, 2025 |
| Nov 15, 2025 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -390 | $0.00 | $0 | 1,954 | Nov 18, 2025 |
| Nov 15, 2025 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -331 | $0.00 | $0 | 2,989 | Nov 18, 2025 |
Related signals
Other insiders at Seres Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Seres Therapeutics, Inc. | Thomas DesRosier See Remarks | $661 78 shares | -1% | |
| 0Weak | Seres Therapeutics, Inc. | Matthew R Henn See Remarks | $754 89 shares | -1% | |
| 0Weak | Seres Therapeutics, Inc. | Thomas DesRosier See Remarks | $1,315 76 shares | -1% | |
| 0Weak | Seres Therapeutics, Inc. | Matthew R Henn See Remarks | $22k 1,257 shares | -14% | |
| 0Weak | Seres Therapeutics, Inc. | Teresa L. Young See Remarks | $18k 1,042 shares | -11% | |
| 0Weak | Seres Therapeutics, Inc. | Thomas DesRosier See Remarks | $1,265 76 shares | -1% | |
| 0Weak | Seres Therapeutics, Inc. | Matthew R Henn See Remarks | $1,215 73 shares | -2% | |
| 0Weak | Seres Therapeutics, Inc. | Eric D. Shaff CEO and President | $3,613 217 shares | -2% | |
| 0Weak | Seres Therapeutics, Inc. | Teresa L. Young See Remarks | $982 59 shares | -1% | |
| 0Weak | Seres Therapeutics, Inc. | Thomas DesRosier Chief Legal Officer and EVP | $575 79 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.